Literature DB >> 25243660

Lamotrigine can be beneficial in patients with Dravet syndrome.

Linda Dalic1, Saul A Mullen, Eliane Roulet Perez, Ingrid Scheffer.   

Abstract

Dravet syndrome, a severe infantile epilepsy syndrome, is typically resistant to anti-epileptic drugs (AED). Lamotrigine (LTG), an AED that is effective for both focal and generalized seizures, has been reported to aggravate seizures in Dravet syndrome. Therefore, LTG is usually avoided in Dravet syndrome. We describe two adults and a child with Dravet syndrome in whom LTG resulted in decreased seizure duration and frequency. This benefit was highlighted in each patient when LTG was withdrawn after 6 to 15 years, and resulted in an increased frequency of convulsive seizures together with longer seizure duration. A 25-year-old male required hospital admission for frequent seizures for the first time in 7 years, 6 weeks after ceasing LTG. Reintroduction of LTG improved seizure control, suggesting that in some patients with Dravet syndrome, LTG may be beneficial.
© 2014 Mac Keith Press.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25243660     DOI: 10.1111/dmcn.12593

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  11 in total

Review 1.  Treatment Strategies for Dravet Syndrome.

Authors:  Kelly G Knupp; Elaine C Wirrell
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

Review 2.  Current Treatment Strategies and Future Treatment Options for Dravet Syndrome.

Authors:  Julie Ziobro; Krista Eschbach; Joseph E Sullivan; Kelly G Knupp
Journal:  Curr Treat Options Neurol       Date:  2018-10-13       Impact factor: 3.598

Review 3.  Rational Small Molecule Treatment for Genetic Epilepsies.

Authors:  Ethan M Goldberg
Journal:  Neurotherapeutics       Date:  2021-08-24       Impact factor: 6.088

4.  A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway.

Authors:  Katrine Heger; Caroline Lund; Margrete Larsen Burns; Marit Bjørnvold; Erik Sætre; Svein I Johannessen; Cecilie Johannessen Landmark
Journal:  Epilepsia Open       Date:  2020-07-06

Review 5.  Recent Advances in the Drug Treatment of Dravet Syndrome.

Authors:  Elaine C Wirrell; Rima Nabbout
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749

6.  A Transient Developmental Window of Fast-Spiking Interneuron Dysfunction in a Mouse Model of Dravet Syndrome.

Authors:  Morgana Favero; Nathaniel P Sotuyo; Emily Lopez; Jennifer A Kearney; Ethan M Goldberg
Journal:  J Neurosci       Date:  2018-08-13       Impact factor: 6.167

7.  Audit of use of stiripentol in adults with Dravet syndrome.

Authors:  S Balestrini; S M Sisodiya
Journal:  Acta Neurol Scand       Date:  2016-05-27       Impact factor: 3.209

Review 8.  Pharmacogenomics in epilepsy.

Authors:  Simona Balestrini; Sanjay M Sisodiya
Journal:  Neurosci Lett       Date:  2017-01-10       Impact factor: 3.046

Review 9.  Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe.

Authors:  Elena Cardenal-Muñoz; Stéphane Auvin; Vicente Villanueva; J Helen Cross; Sameer M Zuberi; Lieven Lagae; José Ángel Aibar
Journal:  Epilepsia Open       Date:  2021-12-19

10.  A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects
.

Authors:  Brooks Boyd; Steven Smith; Arnold Gammaitoni; Bradley S Galer; Gail M Farfel
Journal:  Int J Clin Pharmacol Ther       Date:  2019-01       Impact factor: 1.366

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.